The University of Sheffield and Pfizer have launched a new consortium which aims to standardise and accelerate the development of Advanced Therapy Medicinal Products (ATMPs), allowing potentially transformative treatments to reach patients sooner.
Production bottlenecks are the major obstacle to large-scale commercial manufacture once more advanced therapy medicinal products (ATMPs) are approved.